The triple screen test is a prenatal blood test conducted during the second trimester to assess the risk of certain genetic disorders, such as Down syndrome, trisomy 18, and neural tube defects. It measures levels of three substances in the mother's blood: alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG), and unconjugated estriol (uE3).